Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dave Morgan

Showing results (41-50 of 89) with videos related to

Pageof 9
Sort By:
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 9, 2003
Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activationDonna M Wilcock, Giovanni DiCarlo, Debbi Henderson, et al.
Neurobiology of Aging|June 19, 2016
Metabolic changes over the course of aging in a mouse model of tau depositionAurélie Joly-Amado, Karisa S Serraneau, Milene Brownlow, et al.
Journal of Neuroinflammation|September 13, 2011
Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrenceDonna M Wilcock, Dave Morgan, Marcia N Gordon, et al.
Journal of Neurochemistry|December 24, 2003
Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic miceChad A Dickey, Marcia N Gordon, Jerimiah E Mason, et al.
ASN Neuro|October 15, 2011
Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responsesDonna M Wilcock, Qun Zhao, Dave Morgan, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 12, 2017
Adeno-associated Viral (AAV) Serotype 5 Vector Mediated Gene Delivery of Endothelin-converting Enzyme Reduces Aβ Deposits in APP + PS1 Transgenic MiceNiki C Carty, Kevin Nash, Daniel Lee, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 31, 2008
Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic miceNiki C Carty, Kevin Nash, Daniel Lee, et al.
Research Square|June 3, 2024
Validation of a functional human AD model with four AD therapeutics utilizing patterned iPSC-derived cortical neurons integrated with microelectrode arraysJulbert Caneus, Kaveena Autar, Nesar Akanda, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|July 9, 2008
Deglycosylated anti-Abeta antibody dose-response effects on pathology and memory in APP transgenic miceRachel A Karlnoski, Arnon Rosenthal, Jennifer Alamed, et al.
Neuro-Degenerative Diseases|July 17, 2012
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathyMaj-Linda B Selenica, Milene Brownlow, Jeffy P Jimenez, et al.
Pageof 9

Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 9, 2003
Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activationDonna M Wilcock, Giovanni DiCarlo, Debbi Henderson, et al.
Neurobiology of Aging|June 19, 2016
Metabolic changes over the course of aging in a mouse model of tau depositionAurélie Joly-Amado, Karisa S Serraneau, Milene Brownlow, et al.
Journal of Neuroinflammation|September 13, 2011
Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrenceDonna M Wilcock, Dave Morgan, Marcia N Gordon, et al.
Journal of Neurochemistry|December 24, 2003
Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic miceChad A Dickey, Marcia N Gordon, Jerimiah E Mason, et al.
ASN Neuro|October 15, 2011
Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responsesDonna M Wilcock, Qun Zhao, Dave Morgan, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 12, 2017
Adeno-associated Viral (AAV) Serotype 5 Vector Mediated Gene Delivery of Endothelin-converting Enzyme Reduces Aβ Deposits in APP + PS1 Transgenic MiceNiki C Carty, Kevin Nash, Daniel Lee, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 31, 2008
Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic miceNiki C Carty, Kevin Nash, Daniel Lee, et al.
Research Square|June 3, 2024
Validation of a functional human AD model with four AD therapeutics utilizing patterned iPSC-derived cortical neurons integrated with microelectrode arraysJulbert Caneus, Kaveena Autar, Nesar Akanda, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|July 9, 2008
Deglycosylated anti-Abeta antibody dose-response effects on pathology and memory in APP transgenic miceRachel A Karlnoski, Arnon Rosenthal, Jennifer Alamed, et al.
Neuro-Degenerative Diseases|July 17, 2012
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathyMaj-Linda B Selenica, Milene Brownlow, Jeffy P Jimenez, et al.
Pageof 9